Trial Outcomes & Findings for ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (NCT NCT01001377)
NCT ID: NCT01001377
Last Updated: 2022-09-21
Results Overview
Overall survival is the time from the date of randomization until the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date.
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
1010 participants
Primary outcome timeframe
From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Results posted on
2022-09-21
Participant Flow
First patient enrolled on 2nd February 2010 and last patient enrolled 19 July 2012. Results are reported as of the data cut-off date of 5 February 2013.
Participant milestones
| Measure |
Cetuximab
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Overall Study
STARTED
|
504
|
506
|
|
Overall Study
Received Treatment
|
500
|
499
|
|
Overall Study
COMPLETED
|
78
|
85
|
|
Overall Study
NOT COMPLETED
|
426
|
421
|
Reasons for withdrawal
| Measure |
Cetuximab
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Overall Study
Ineligibility determined
|
2
|
0
|
|
Overall Study
Withdrawal by Subject
|
19
|
20
|
|
Overall Study
Lost to Follow-up
|
14
|
17
|
|
Overall Study
Death
|
391
|
384
|
Baseline Characteristics
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Baseline characteristics by cohort
| Measure |
Cetuximab
n=504 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=506 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
Total
n=1010 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
60.2 years
STANDARD_DEVIATION 11.2 • n=5 Participants
|
59.6 years
STANDARD_DEVIATION 10.9 • n=7 Participants
|
59.9 years
STANDARD_DEVIATION 11.1 • n=5 Participants
|
|
Sex: Female, Male
Female
|
183 Participants
n=5 Participants
|
187 Participants
n=7 Participants
|
370 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
321 Participants
n=5 Participants
|
319 Participants
n=7 Participants
|
640 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian
|
230 participants
n=5 Participants
|
225 participants
n=7 Participants
|
455 participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
4 participants
n=5 Participants
|
2 participants
n=7 Participants
|
6 participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Hispanic or Latino
|
7 participants
n=5 Participants
|
6 participants
n=7 Participants
|
13 participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Japanese
|
0 participants
n=5 Participants
|
1 participants
n=7 Participants
|
1 participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Other
|
3 participants
n=5 Participants
|
2 participants
n=7 Participants
|
5 participants
n=5 Participants
|
|
Race/Ethnicity, Customized
White or Caucasian
|
260 participants
n=5 Participants
|
270 participants
n=7 Participants
|
530 participants
n=5 Participants
|
|
Geographic region
North America, Western Europe and Australia
|
158 participants
n=5 Participants
|
158 participants
n=7 Participants
|
316 participants
n=5 Participants
|
|
Geographic region
Rest of World
|
346 participants
n=5 Participants
|
348 participants
n=7 Participants
|
694 participants
n=5 Participants
|
|
Eastern Cooperative Oncology Group (ECOG) performance status
Grade 0
|
165 participants
n=5 Participants
|
155 participants
n=7 Participants
|
320 participants
n=5 Participants
|
|
Eastern Cooperative Oncology Group (ECOG) performance status
Grade 1
|
299 participants
n=5 Participants
|
309 participants
n=7 Participants
|
608 participants
n=5 Participants
|
|
Eastern Cooperative Oncology Group (ECOG) performance status
Grade 2
|
40 participants
n=5 Participants
|
42 participants
n=7 Participants
|
82 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.Population: Primary Analysis Set: All participants who were randomized and who received at least 1 dose of panitumumab or cetuximab; analyzed according to randomized treatment arm.
Overall survival is the time from the date of randomization until the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date.
Outcome measures
| Measure |
Cetuximab
n=500 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=499 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Overall Survival
|
10.0 months
Interval 9.3 to 11.0
|
10.4 months
Interval 9.4 to 11.6
|
SECONDARY outcome
Timeframe: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.Population: Primary analysis set
Progression free survival (PFS) is the time from the date of randomization to the date of disease progression per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death. Participants alive and not meeting criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study based on all target lesions recorded since the treatment started (the sum must also demonstrate an absolute increase of at least 5 mm), or unequivocal progression of existing non-target lesions, or any new lesions.
Outcome measures
| Measure |
Cetuximab
n=500 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=499 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Progression-free Survival
|
4.4 months
Interval 3.2 to 4.8
|
4.1 months
Interval 3.2 to 4.8
|
SECONDARY outcome
Timeframe: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.Population: Tumor Response Analysis Set: Participants in the primary analysis set with at least 1 Baseline unidimensionally measurable lesion per RECIST version 1.1.
Objective response is either a complete response (CR) or partial response (PR) per RECIST version 1.1. All participants that did not meet the criteria for an objective response by the analysis cut-off date were considered non-responders. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and disappearance of all non-target lesions, and no new lesions. PR: Disappearance of all target lesions, persistence of one or more non-target lesions not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of diameters of target lesions with no unequivocal progression of existing non-target lesions and no new lesions.
Outcome measures
| Measure |
Cetuximab
n=485 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=486 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Objective Response
|
19.79 percentage of participants
Interval 16.34 to 23.62
|
22.02 percentage of participants
Interval 18.41 to 25.97
|
SECONDARY outcome
Timeframe: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.Population: Participants with an objective response
Duration of response (DOR), calculated only for those participants with an objective response, is the time from first objective response to disease progression per the RECIST v1.1 or death. Participants not meeting criteria for progression or who died by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Outcome measures
| Measure |
Cetuximab
n=96 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=107 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Duration of Response
|
5.4 months
Interval 3.8 to 5.5
|
3.8 months
Interval 3.7 to 4.8
|
SECONDARY outcome
Timeframe: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.Population: Participants with an objective response
Time to response (TTR), calculated for those participants with an objective response, is defined as the time from the randomization date to the date of first objective response.
Outcome measures
| Measure |
Cetuximab
n=96 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=107 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Time to Response
|
2.6 months
Interval 1.2 to 3.1
|
1.5 months
Interval 1.2 to 3.0
|
SECONDARY outcome
Timeframe: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.Population: Primary analysis set
Time to treatment failure (TTF) is the time from randomization date to date that the decision was made to end the treatment period for any reason; participants who remained in the treatment period at the time of analysis were censored at the date of the last on-study assessment.
Outcome measures
| Measure |
Cetuximab
n=500 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=499 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Time to Treatment Failure
|
3.3 months
Interval 3.2 to 3.9
|
3.4 months
Interval 3.2 to 4.6
|
SECONDARY outcome
Timeframe: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.Population: Patient reported outcomes (PRO) analysis set: all participants in the primary analysis set who have a Baseline and at least one follow-up PRO assessment prior to clinical or objective disease progression per RECIST version 1.1. Participants with available data are included.
The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The health state index measures the following 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension contains 3 levels of response to reflect degree of problems participants have experienced: no problem (1), some problem (2) and extreme problems (3). The health states for each respondent are converted into a single index number using a specified set of weights. Resulting scores can range from 1.0 and -0.594. A higher score indicates a more preferred health status with 1.0 representing perfect health and 0 representing death. Negative scores are possible and represent health states regarded as less preferable than death (0). Repeated measures mixed model includes treatment, geographic region, ECOG score, assessment week, and treatment by assessment week interaction as fixed effects, and participants a random effect.
Outcome measures
| Measure |
Cetuximab
n=150 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=143 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score
|
-0.0341 scores on a scale
Interval -0.0806 to 0.0123
|
-0.0216 scores on a scale
Interval -0.0691 to 0.026
|
SECONDARY outcome
Timeframe: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.Population: Patient reported outcomes (PRO) analysis set participants with available data
The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The VAS asks respondents to rate their present health status on a 0 - 100 scale, with 0 labeled as "Worst imaginable health state" and 100 labeled as "Best imaginable health state." The VAS score is determined by observing the point at which the participant's hand drawn line intersects the scale.
Outcome measures
| Measure |
Cetuximab
n=149 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=142 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS)
|
3.9782 scores on a scale
Interval 0.8842 to 7.0722
|
2.3037 scores on a scale
Interval -0.8532 to 5.4605
|
SECONDARY outcome
Timeframe: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.Population: Patient reported outcomes (PRO) analysis set participants with available data.
The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).
Outcome measures
| Measure |
Cetuximab
n=151 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=142 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Change From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score
|
2.0101 scores on a scale
Interval -1.1477 to 5.1679
|
3.0473 scores on a scale
Interval -0.1782 to 6.2728
|
SECONDARY outcome
Timeframe: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.Population: Patient reported outcomes (PRO) analysis set participants with available data.
The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).
Outcome measures
| Measure |
Cetuximab
n=150 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=142 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Change From Baseline in NCCN FCSI Physical Well-being Scale Score
|
1.8778 scores on a scale
Interval -1.5524 to 5.308
|
2.4614 scores on a scale
Interval -1.0442 to 5.967
|
SECONDARY outcome
Timeframe: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.Population: Patient reported outcomes (PRO) analysis set participants with available data.
The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).
Outcome measures
| Measure |
Cetuximab
n=152 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=143 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Change From Baseline in NCCN FCSI Functional Well-being Scale Score
|
1.3567 scores on a scale
Interval -4.1564 to 6.8697
|
1.1569 scores on a scale
Interval -4.4887 to 6.8025
|
SECONDARY outcome
Timeframe: From the day of the first dose of study therapy through 30 days since the last dose. Maximum time on study treatment was 130 weeks.Population: Safety Analysis Set (randomized participants who received at least 1 dose of study medication). Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses.
Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs are those the investigator considered as a reasonable possibility to have been caused by study drug.
Outcome measures
| Measure |
Cetuximab
n=503 Participants
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=496 Participants
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Number of Participants With Adverse Events (AEs)
Leading to discontinuation of study drug
|
61 participants
|
69 participants
|
|
Number of Participants With Adverse Events (AEs)
Any treatment-related adverse event (TRAE)
|
459 participants
|
437 participants
|
|
Number of Participants With Adverse Events (AEs)
Any adverse event (AE)
|
494 participants
|
485 participants
|
|
Number of Participants With Adverse Events (AEs)
Serious adverse events
|
169 participants
|
151 participants
|
|
Number of Participants With Adverse Events (AEs)
Treatment-related serious adverse event
|
22 participants
|
25 participants
|
|
Number of Participants With Adverse Events (AEs)
TRAE leading to discontinuation of study drug
|
15 participants
|
14 participants
|
Adverse Events
Cetuximab
Serious events: 169 serious events
Other events: 474 other events
Deaths: 0 deaths
Panitumumab
Serious events: 151 serious events
Other events: 459 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Cetuximab
n=503 participants at risk
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=496 participants at risk
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Vascular disorders
Artery dissection
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Vascular disorders
Deep vein thrombosis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Vascular disorders
Embolism
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Vascular disorders
Lymphocele
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Vascular disorders
Superior vena cava syndrome
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Vascular disorders
Thrombosis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.60%
3/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.2%
6/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Cardiac disorders
Atrial fibrillation
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Cardiac disorders
Cardiomyopathy
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Cardiac disorders
Cardiopulmonary failure
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Cardiac disorders
Cardiovascular insufficiency
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.80%
4/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Abdominal mass
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Abdominal pain
|
2.6%
13/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
2.0%
10/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.60%
3/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Ascites
|
0.99%
5/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.0%
5/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Colitis
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Constipation
|
0.60%
3/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Diarrhoea
|
1.6%
8/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.2%
6/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Duodenal obstruction
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Faecaloma
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Gastritis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Gastrointestinal obstruction
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Haematochezia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Ileus
|
0.99%
5/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.0%
5/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Intestinal infarction
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
1.6%
8/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
2.4%
12/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Large intestine perforation
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Melaena
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Mesenteric vein thrombosis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Nausea
|
0.99%
5/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Obturator hernia
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Peritoneal adhesions
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Rectal polyp
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Rectal tenesmus
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.60%
3/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.81%
4/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Small intestinal perforation
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Subileus
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Vomiting
|
0.99%
5/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
2.4%
12/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Asthenia
|
0.80%
4/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.2%
6/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Chest discomfort
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Chest pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Death
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Device occlusion
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Fatigue
|
0.80%
4/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.81%
4/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Gait disturbance
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
General physical health deterioration
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Hyperpyrexia
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Malaise
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Multi-organ failure
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Oedema
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Oedema peripheral
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Pain
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Performance status decreased
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Pyrexia
|
1.6%
8/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.60%
3/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Systemic inflammatory response syndrome
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Bile duct obstruction
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Cholangitis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Cholestasis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Hepatic failure
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Hepatic function abnormal
|
0.80%
4/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Hepatic lesion
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Hepatocellular injury
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.80%
4/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Jaundice
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.60%
3/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Jaundice cholestatic
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Hepatobiliary disorders
Jaundice extrahepatic obstructive
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Immune system disorders
Anaphylactic reaction
|
0.60%
3/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Immune system disorders
Cytokine release syndrome
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Immune system disorders
Hypersensitivity
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Abdominal abscess
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Abscess limb
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Anal abscess
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Bacteraemia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Bronchopneumonia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Cellulitis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Cystitis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Device related infection
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Device related sepsis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Enterococcal infection
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Escherichia infection
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Furuncle
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Gastroenteritis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Gastrointestinal infection
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Herpes zoster
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Infected dermal cyst
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Infection
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Lobar pneumonia
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Lung infection
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Nail infection
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Neutropenic sepsis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Paronychia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Peritonitis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Pneumonia
|
1.4%
7/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Pyelonephritis acute
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Pyonephrosis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Sepsis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.0%
5/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Septic shock
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Subcutaneous abscess
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Tooth abscess
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Urinary bladder abscess
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Urinary tract infection
|
1.4%
7/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.8%
9/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Cervical vertebral fracture
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Laceration
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Poisoning
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Scapula fracture
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Soft tissue injury
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Injury, poisoning and procedural complications
Wound complication
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Investigations
Blood bilirubin increased
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Investigations
Blood creatine increased
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Investigations
Blood creatinine increased
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Investigations
Blood uric acid increased
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Investigations
Red blood cell count decreased
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.60%
3/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Fluid overload
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.81%
4/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.60%
3/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.81%
4/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Muscle haemorrhage
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Pathological fracture
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.99%
5/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.0%
5/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer metastatic
|
1.2%
6/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.81%
4/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer
|
2.0%
10/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.4%
7/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer metastatic
|
2.8%
14/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
1.4%
7/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Infected neoplasm
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.81%
4/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to liver
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to meninges
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to ovary
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to spine
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour necrosis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour thrombosis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Altered state of consciousness
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Carotid artery stenosis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Central nervous system lesion
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Cerebral infarction
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Convulsion
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Dyskinesia
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Loss of consciousness
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Spinal cord compression
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Syncope
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Psychiatric disorders
Confusional state
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Psychiatric disorders
Depression
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Azotaemia
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Bladder dilatation
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Dysuria
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Haematuria
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.40%
2/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.81%
4/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Obstructive uropathy
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Oliguria
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Renal failure
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Renal failure acute
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Renal failure chronic
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Renal impairment
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Ureteric stenosis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Reproductive system and breast disorders
Female genital tract fistula
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Reproductive system and breast disorders
Oedema genital
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Reproductive system and breast disorders
Perineal pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
1.2%
6/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.60%
3/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.60%
3/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.40%
2/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory depression
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory distress
|
0.20%
1/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.60%
3/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.00%
0/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Surgical and medical procedures
Central venous catheterisation
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Surgical and medical procedures
Salpingo-oophorectomy bilateral
|
0.00%
0/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
0.20%
1/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
Other adverse events
| Measure |
Cetuximab
n=503 participants at risk
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
|
Panitumumab
n=496 participants at risk
Panitumumab 6 mg/kg IV every 14 days.
|
|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
6.0%
30/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
5.8%
29/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Abdominal pain
|
14.7%
74/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
10.5%
52/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Constipation
|
13.9%
70/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
7.9%
39/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Diarrhoea
|
17.3%
87/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
17.7%
88/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Dyspepsia
|
5.2%
26/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
3.8%
19/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Nausea
|
11.1%
56/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
13.3%
66/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Stomatitis
|
6.8%
34/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
5.2%
26/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Gastrointestinal disorders
Vomiting
|
9.7%
49/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
9.9%
49/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Asthenia
|
8.7%
44/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
6.0%
30/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Fatigue
|
16.9%
85/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
14.5%
72/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Oedema peripheral
|
7.6%
38/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
4.4%
22/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
General disorders
Pyrexia
|
9.9%
50/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
5.6%
28/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Paronychia
|
14.9%
75/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
11.7%
58/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Infections and infestations
Upper respiratory tract infection
|
5.6%
28/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
2.8%
14/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Investigations
Weight decreased
|
4.2%
21/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
5.2%
26/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
15.3%
77/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
13.9%
69/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
3.2%
16/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
5.2%
26/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
4.6%
23/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
8.3%
41/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
17.7%
89/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
27.0%
134/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
7.4%
37/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
6.9%
34/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Nervous system disorders
Headache
|
7.2%
36/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
3.4%
17/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Psychiatric disorders
Insomnia
|
9.1%
46/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
5.4%
27/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
7.6%
38/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
8.1%
40/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
6.6%
33/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
3.8%
19/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Skin and subcutaneous tissue disorders
Acne
|
13.7%
69/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
10.5%
52/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
27.0%
136/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
27.8%
138/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
15.7%
79/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
16.7%
83/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Skin and subcutaneous tissue disorders
Nail disorder
|
6.2%
31/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
5.2%
26/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
17.5%
88/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
16.7%
83/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Skin and subcutaneous tissue disorders
Rash
|
51.1%
257/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
50.2%
249/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
|
Skin and subcutaneous tissue disorders
Skin fissures
|
8.5%
43/503 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
8.5%
42/496 • Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.
Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses. The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
|
Additional Information
Study Director
Amgen Inc.
Phone: 866-572-6436
Results disclosure agreements
- Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
- Publication restrictions are in place
Restriction type: OTHER